Phase 1 Randomized, Double-blind, Three Period, Crossover Study Comparing PD/PK, Safety and Tolerability Profiles for Arecor Ultra-rapid Insulin Aspart (AT247), NovoLog® and Fiasp® in Participants With T1DM During CSII

Phase 1 randomized, double-blind, three period, crossover study comparing the pharmacodynamic, pharmacokinetic, safety and tolerability profiles for Arecor ultra-rapid insulin aspart (AT247), NovoLog® and Fiasp® in participants with type 1 diabetes mellitus (T1DM) during continuous subcutaneous infusion (CSII)

开始日期2022-01-03

申办/合作机构

Arecor Ltd.

NCT03959514

/ Completed临床1期

Phase I Single Dose, Randomised, Double-blind, Three-way Cross Over, Glucose Clamp Study Investigating the PK/PD and Safety of Arecor Ultra-rapid Insulin Aspart (AT247) in Comparison to NovoRapid® and Fiasp® in Participants With Type I Diabetes Mellitus (T1DM).

A Phase I, randomised, single-centre, double-blind, single-dose, three period, balanced cross over study in a glucose clamp setting. The study compares the pharmacodynamic, pharmacokinetic and safety characteristics of AT247, NovoRapid® and Fiasp® in male participants with type I diabetes mellitus.

开始日期2019-04-12

申办/合作机构

Arecor Ltd.

DRKS00013509

/ CompletedN/AIIT

Influence of adjusting rapid-acting insulin aspart on post-exercise nocturnal hypoglycaemia in recreationally active people with type 1 diabetes on insulin degludec - HypEx

开始日期2017-07-20

申办/合作机构-

100 项与 AT-247 相关的临床结果

登录后查看更多信息

100 项与 AT-247 相关的转化医学

登录后查看更多信息

100 项与 AT-247 相关的专利（医药）

登录后查看更多信息

项与 AT-247 相关的文献（医药）

2024-11-01·DIABETOLOGIA

Assessing the influence of insulin type (ultra-rapid vs rapid insulin) and exercise timing on postprandial exercise-induced hypoglycaemia risk in individuals with type 1 diabetes: a randomised controlled trial

Article

作者: Molveau, Joséphine ; Tagougui, Sémah ; St-Amand, Roxane ; Rabasa-Lhoret, Rémi ; Myette-Côté, Étienne ; Heyman, Elsa ; Taleb, Nadine ; Suppère, Corinne ; Bourdeau, Valérie

AIMS/HYPOTHESIS:

The relationship between pre-meal insulin type, exercise timing and the risk of postprandial exercise-induced hypoglycaemia in people living with type 1 diabetes is unknown. We aimed to evaluate the effects of exercise timing (60 vs 120 min post meal) and different insulin types (aspart vs ultra-rapid aspart) on hypoglycaemic risk.

METHODS:

This was a four-way crossover randomised trial including 40 individuals with type 1 diabetes using multiple daily injections (mean HbA_1c 56 mmol/mol [7.4%]). Participants, who were recruited from the Montreal Clinical Research Institute, undertook 60 min cycling sessions (60% of __-mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"-__ V ˙ O 2 peak ) after breakfast (60 min [EX60min] or 120 min [EX120min] post meal) with 50% of their usual insulin dose (aspart or ultra-rapid aspart). Eligibility criteria included age ≥18 years old, clinical diagnosis of type 1 diabetes for at least 1 year and HbA_1c ≤80 mmol/mol (9.5%). Participants were allocated using sequentially numbered, opaque sealed envelopes. Participants were masked to their group assignment, and each participant was allocated a unique identification number to ensure anonymisation. The primary outcome was change in blood glucose levels between exercise onset and nadir.

RESULTS:

Prior to exercise onset, time spent in hyperglycaemia was lower for EX60min vs EX120min (time >10.0 mmol/l: 56.6% [1.2-100%] vs 78.0% [52.7-97.9%]; p<0.001). The glucose reduction between exercise onset and nadir was less pronounced with EX60min vs EX120min (-3.8±2.7 vs -4.7±2.5 mmol/l; p<0.001). A similar number of hypoglycaemic events occurred during both exercise timings. Blood glucose between exercise onset and nadir decreased less with ultra-rapid aspart compared with aspart (-4.1±2.3 vs -4.4±2.8 mmol/l; p=0.037). While a similar number of hypoglycaemic events during exercise were observed, less post-exercise hypoglycaemia occurred with ultra-rapid aspart (n=0, 0%, vs n=15, 38%; p=0.003). No interactions between insulin types and exercise timings were found.

CONCLUSIONS/INTERPRETATION:

EX60min blunted the pre-exercise glucose increase following breakfast and was associated with a smaller glucose reduction during exercise. Ultra-rapid aspart led to a smaller blood glucose reduction during exercise and might be associated with diminished post-exercise hypoglycaemia.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT03659799 FUNDING: This study was funded by Novo Nordisk Canada.

2024-08-01·Internal medicine journal

Glycaemic outcomes in hospital with IDegAsp versus BIAsp30 premixed insulins

Article

作者: Varadarajan, Suresh ; Zhu, Jasmine ; Kyi, Mervyn ; Fourlanos, Spiros ; Walt, Joshua R ; Loughran, Julie ; Barmanray, Rahul D

Abstract:

Background and Aims:

IDegAsp (Ryzodeg 70/30), a unique premixed formulation of long‐acting insulin degludec and rapid‐acting insulin aspart, is increasing in use. Management of IDegAsp during hospitalisation is challenging because of degludec's ultra‐long duration of action. We investigated inpatient glycaemia in patients treated with IDegAsp compared to biphasic insulin aspart (BIAsp30; Novomix30).

Methods:

We performed a retrospective observational study at two hospitals assessing inpatients with type 2 diabetes treated with IDegAsp or BIAsp30 prior to and during hospital admission. Standard inpatient glycaemic outcomes were analysed based on capillary blood glucose (BG) measurements.

Results:

We assessed 88 individuals treated with IDegAsp and 88 HbA1c‐matched individuals treated with BIAsp30. Patient characteristics, including insulin dose at admission, were well matched, but the IDegAsp group had less frequent twice‐daily insulin dosing than the BIAsp30 group (49% vs 87%, P < 0.001). Patient‐days with BG <4 mmol/L were not different (10.6% vs 9.9%, P = 0.7); however, the IDegAsp group had a higher patient‐day mean BG (10.4 (SD 3.4) vs 10.0 (3.4) mmol/L, P < 0.001), and more patient‐days with mean BG >10 mmol/L (48% vs 38%, P < 0.001) compared to the BIAsp30 group. Glucose was higher in the IDegAsp group in the evening (4 PM to midnight) (11.6 (SD 4.0) vs 10.9 (4.6) mmol/L, P = 0.004), but not different at other times during the day.

Conclusions:

Inpatients treated with IDegAsp compared to BIAsp30 had similar hypoglycaemia incidence, but higher hyperglycaemia incidence, potentially related to less frequent twice‐daily dosing. With the increasing use of IDegAsp in the community, development of hospital management guidelines for this insulin formulation is needed.

2024-07-10·Cureus Journal of Medical Science

The Effects of Subcutaneous Rapid-Acting Insulin Aspart in the Treatment of Mild and Moderate Diabetic Ketoacidosis in Children: A Prospective Study

Article

作者: Talebi, Hanieh ; Khazaei, Salman ; Razavi, Zahra

Background and objectives The traditional treatment approach to diabetic ketoacidosis (DKA) involves the replacement of fluid and electrolyte deficits and a continuous intravenous infusion of regular insulin. Several clinical trials supported the administration of subcutaneous rapid-acting insulin analogs in the management of uncomplicated DKA. This study aimed to determine the effects/safety of subcutaneous rapid-acting insulin aspart injections in treating uncomplicated mild and moderate DKA in children. Methods In this prospective study in 2022, 25 children with mild/or moderate DKA were enrolled. The main outcome measure was median time (hours) for the resolution of ketoacidosis. Data recorded were as follows: clinical characteristics, severity of ketoacidosis and dehydration, blood glucose, sodium, potassium, creatinine, urine ketones, hospitalization's duration, and complications. Based on the degree of dehydration, fluid deficit was replaced by sodium chloride 0.45%. Insulin aspart 0.15 units/kg subcutaneous injections were given every 2 hours in the hospital outside ICU. Blood glucose was measured hourly and blood gases every 2 hours. Ketoacidosis was considered resolved when the patient did not have nausea/vomiting, was conscious, and could eat, and blood glucose was <250 mg/dL, pH was >7.30, and/or HCO₃ was >15 mmol/L. Results Of 25 DKA patients (mean age 11.06±3.89, range 4-17 years, 60% girls), 16 cases (64%) had established type 1 diabetes. Overall, 13 (52%) cases had mild ketoacidosis (average pH=7.25), and 12 (48%) cases had moderate ketoacidosis (average pH=7.15). The mean time to resolution of ketoacidosis was 11.24 hours. All but one patient met DKA recovery criteria without complications. Mild cases compared to moderate cases of DKA had a shorter duration to resolution of DKA (p = 0.04). Mean duration of hospitalization was 2.3 days. No electrolyte disturbances, hypoglycemia events, readmission or mortality, or other adverse effects were observed. Conclusion In children with mild and moderate DKA, subcutaneous rapid-acting insulin aspart administration was an effective, safe, and convenient treatment.

项与 AT-247 相关的新闻（医药）

2024-05-09

·GlobeNewswire-Health Care

Arecor and Medtronic Diabetes establish collaboration to develop a novel thermostable insulin for implantable pump delivery

Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND MEDTRONIC DIABETES ESTABLISH COLLABORATION TO DEVELOP A NOVEL THERMOSTABLE INSULIN FOR IMPLANTABLE PUMP DELIVERY Medtronic to fund Arecor’s development of Arestat™ enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination with a next-generation implantable pump Cambridge, UK, 9 May 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announced a research collaboration with Medtronic plc (NYSE: MDT), a global leader in healthcare technology, to develop a novel, high concentration, thermostable insulin for use by Medtronic’s Diabetes business in a next-generation implantable pump. This new insulin has the potential to bring significant advancements in the current insulin treatment options for a small population of patients who have limited options for controlling their diabetes with traditional therapy. This collaboration has the potential to allow for the continued care of these patients with an insulin that may minimise the need for pump maintenance interventions and expand the utility for physicians, whilst saving healthcare costs. Sarah Howell, Chief Executive Officer of Arecor, said: “Our leadership in this field has been demonstrated through our best-in-class ultra-rapid acting clinical development programmes (AT278 & AT247). Within the diabetes field more broadly we are seeing the rise of innovative delivery devices, including longer-wear and miniaturised pumps that are continually improving treatment options for patients. We are excited to play our part in this progress with the development of a highly differentiated insulin with the potential to transform treatment for an extremely vulnerable patient group. This collaboration is one of many we hope to enable, to further enhance the benefits of these next-generation devices.” Gary Dulak, Senior Director, New Venture Programs Medtronic Diabetes, said: “Medtronic Diabetes is a pioneer in implantable insulin pump systems for people living with type 1 diabetes, who are unable to tolerate conventional therapy that delivers insulin subcutaneously (under the skin). With intraperitoneal therapy via an implantable insulin pump system, insulin delivery is targeted for direct absorption by the liver via the implantable pump. We are pleased to collaborate with Arecor to explore new ways to develop this critical therapeutic option for the subset of individuals who may benefit from it.” This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 (“UK MAR”). Product not approved by the FDA for any use and not available for research or commercial use in the US. -ENDS- For more information, please contact: Arecor Therapeutics plcwww.arecor.comDr Sarah Howell, Chief Executive OfficerTel: +44 (0) 1223 426060Email: info@arecor.com Susan Lowther, Chief Financial OfficerTel: +44 (0) 1223 426060Email: info@arecor.com Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance)Rupert Dearden (Corporate Broking)Tel: +44 (0) 20 7886 2500 WG Partners LLP (Financial Advisor) Nigel Barnes, Satheesh NadarajahDavid Wilson, Claes SpangTel: +44 (0)203 705 9321 ICR Consilium Chris Gardner, David Daley, Lindsey NevilleTel: +44 (0) 20 3709 5700Email: arecor@consilium-comms.com Notes to Editors About Arecor Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. The collaboration adds to Arecor’s broad programme of diabetes focused activities, led by its two lead proprietary clinical development programmes – AT278 and AT247, two ultra-rapid acting insulin candidates that offer the potential to simplify and improve blood glucose control for people living with diabetes and could enable the development of next- generation miniaturised insulin delivery systems and a fully closed loop artificial pancreas system. In March 2024, Arecor established a research collaboration with TRx Biosciences for the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product that would provide a more convenient treatment option for patients with diabetes and obesity. The Group’s specialty pharmaceutical business, Tetris Pharma, commercialises Ogluo®, a glucagon prefilled autoinjector pen for patients living with diabetes suffering from severe hypoglycaemia. For further details please see our website, www.arecor.com

2023-07-20

·GlobeNewswire-Health Care

Arecor: Business Update

Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Strong pipeline of revenue-generating collaborations with major pharmaceutical and biotech companies with further deals anticipated during H2 and beyondSignificant progress across proprietary diabetes focused portfolio with AT278 scheduled to complete within Q4 2023Good partner progress across licensed portfolio Cambridge, UK, 20 July 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today provides a business update and announces that its interim results for the six months ended 30 June 2023 will be issued in mid-September. Arecor is pleased to report strong progress across the business in the first half of 2023, with advances across its in-house and partnered programmes and continued success in the roll-out of Ogluo® in key territories. Arecor looks forward to providing a full update on performance and outlook at the time of its interim results. The Group's unaudited cash position at 30 June 2023 was £8.2 million. Sarah Howell, Chief Executive Officer at Arecor, said: “We have continued to make significant progress across all areas of the business, strengthening the foundations for future growth across our in-house proprietary products and partnered programmes and supported by a revenue contribution from our commercial subsidiary, Tetris Pharma. Later this year we expect key data for AT278 and anticipate further value inflection points within our licensed product portfolio. With further partnerships and collaborations expected, we are continuing towards our ambition of building a significant self-sustaining biopharmaceutical company.” The Group has continued to make strong progress across its proprietary diabetes focused portfolio. The second Phase I clinical trial of AT278 in Type 2 diabetic patients is scheduled to complete within Q4 2023. AT278 is an ultra-rapid, ultra-concentrated (500U/mL) insulin candidate that has been designed to accelerate the absorption of insulin post injection, despite a 5-fold increase in concentration compared with 100U/mL insulins available to patients today. It has the potential to become the gold standard treatment for the growing population of people with diabetes with high daily insulin needs as the first and potentially only concentrated, yet rapid acting insulin. A truly rapid acting, concentrated insulin is also a critical step towards the advancement of the next generation of longer wear and miniaturised insulin delivery devices. Positive results from the Group’s second Phase I clinical trial investigating ultra-rapid acting insulin product candidate, AT247, presented at the American Diabetes Association (ADA) 83rd Scientific Sessions meeting in June 2023, clearly demonstrate faster insulin absorption than current, gold-standard, rapid acting insulins and reinforce AT247’s potential to enable a fully closed loop artificial pancreas – a life changing treatment approach for people living with diabetes. The Group maintains a strong pipeline of revenue-generating collaborations with major pharmaceutical and biotech companies with further deals anticipated in H2 and beyond. In June 2023, the Group entered into a revenue-generating agreement with a leading biopharmaceutical company to support development of a biosimilar product. This collaboration follows an earlier technology partnership between the two companies, further demonstrating the strength and relevance of the Group’s technology platform and expertise. This was the second agreement signed in the first half of 2023, after an additional formulation agreement with an existing Top 5 pharma partner in February, bringing the total number of new technology partnerships signed to 10 since IPO. These partnerships deliver revenue and offer significant upside potential from licensing under milestone and royalty bearing agreements. The Group’s three licensed programmes, under milestone and royalty-based agreements or equivalent, have also advanced. Arecor continues to expect the first product incorporating its Arestat™ technology, AT220, to be commercialised by its partner under a royalty-generating license agreement in a multi-billion dollar market, with US FDA approval anticipated in H2 2023. In addition, Hikma continues to progress AT307, a ready-to-use ("RTU") injectable medicine after its milestone-triggering transfer from Arecor in January 2023. The Group was also pleased to note, in April 2023, that its partner Inhibrx initiated a registration-enabling trial of INBRX-101, an Arestat™ formulated optimized recombinant human AAT-Fc fusion protein, for treatment of patients with emphysema due to alpha-1 antitrypsin deficiency (AATD). Tetris Pharma, the speciality pharmaceutical company acquired by Arecor in August 2022, continues the European commercial roll out of its key diabetes product, Ogluo® (glucagon prefilled autoinjector pen), adding Denmark and Norway in May 2023, to existing markets in Austria, Germany and the UK, and sales continue to grow. During the remainder of H2 2023, Tetris Pharma will focus on accelerating market adoption of Ogluo® and roll-out across key territories. With this continued focus on growing and maximising the value of Ogluo® in the UK and Europe, Dr Shafiq Choudhary, Founder and Managing Director, will be leaving the business later this year following a handover period. The Management Team and Board of Arecor thank Shafiq for his contribution and commitment since the acquisition. The momentum we are seeing and the increasingly pan-European focus of our commercial efforts provide the Group with continued confidence in Ogluo®. Sales of Gvoke® in the US also remain strong with continued quarter on quarter growth and, while the market dynamics clearly differ, the US experience provides further support for the Group’s belief in the growth potential of the product in the UK and Europe. The Group has continued to strengthen its patent portfolio to protect its Arestat™ technology platform and proprietary pipeline products, with six new patent grants this year, most recently, in June 2023, announcing key patents from the European Patent Office and the China National Intellectual Property Administration, protecting novel formulations of AT278 and AT247. The Group's intellectual property (IP) portfolio currently comprises 36 patent families, including >75 granted patents in Europe, the US and in other key territories. This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"). -ENDS- For more information, please contact: Arecor Therapeutics plcwww.arecor.comDr Sarah Howell, Chief Executive OfficerTel: +44 (0) 1223 426060Email: info@arecor.com Susan Lowther, Chief Financial OfficerTel: +44 (0) 1223 426060Email: info@arecor.com Mo Noonan, CommunicationsTel: +44 (0) 7876 444977Email: mo.noonan@arecor.com Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance)Rupert Dearden (Corporate Broking)Tel: +44 (0) 20 7886 2500 Consilium Strategic Communications Chris Gardner, David Daley, Lindsey NevilleTel: +44 (0) 20 3709 5700Email: arecor@consilium-comms.com Notes to EditorsAbout Arecor Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com

临床1期引进/卖出并购

2022-10-11

·GlobeNewswire-Health Care

Headline results from Phase I clinical trial of ultra-rapid acting insulin candidate AT247 demonstrate significantly accelerated insulin absorption and early exposure compared to gold standard insulins NovoLog® and Fiasp®

Arecor Therapeutics plc(“Arecor”, the “Company” or the “Group”) HEADLINE RESULTS FROM PHASE I CLINICAL TRIAL OF ULTRA-RAPID ACTING INSULIN CANDIDATE AT247 DEMONSTRATE SIGNIFICANTLY ACCELERATED INSULIN ABSORPTION AND EARLY EXPOSURE COMPARED TO GOLD STANDARD INSULINS NOVOLOG® AND FIASP® AT247 delivers significantly accelerated insulin absorption and early exposure (PK profile) compared with NovoLog® and Fiasp®, meeting co-primary endpoint AT247 delivers a statistically significant superior glucose lowering effect compared with NovoLog® supporting the accelerated absorption and early exposure PK profileAT247 demonstrated a similar PD profile to Fiasp®. The statistically superior co-primary endpoint was not met AT247 shown to be safe and efficacious when delivered by continuous subcutaneous (SC) infusionFurther supports potential to enable more effective disease management for people with Type I diabetes via fully automated closed loop insulin pump delivery (artificial pancreas) Cambridge, UK, 11 October 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces headline results from the second Phase I clinical trial of its ultra-rapid acting insulin, AT247, which support its potential to facilitate a fully closed loop artificial pancreas. AT247 is a 100U/mL ultra-rapid acting novel formulation of insulin that has been designed to accelerate the absorption of insulin post injection. The superior pharmacokinetics / pharmacodynamics (“PK”/”PD”) profile of a single dose of AT247 compared with gold standard insulins NovoLog® and Fiasp® has been previously demonstrated in a Phase I study. This second clinical study further confirms that AT247 has a superior PK profile compared with NovoLog® and Fiasp®, showing a statistically significant difference meeting the trial’s co-primary endpoint. AT247 also demonstrated a statistically superior early glucose lowering effect in the trial’s second primary endpoint compared with NovoLog® which was calculated from baseline corrected Incremental AUC GIR (Glucose Infusion rate) 0-60min (mg/kg) during post-hoc analysis. In addition, AT247 demonstrated a similar glucose lowering profile to Fiasp®, however it did not meet superiority for this endpoint within this study. The trial further demonstrated that AT247 can be safely and effectively delivered via continuous SC infusion using an insulin pump. With a superior PK profile and promising PD results, this study supports the potential that AT247 can enable even more effective disease management for people with Type I diabetes using fully automated delivery of insulin via a pump in closed loop mode. Dr Victoria Mirza, Principal Investigator for the ARE-AT247-103 clinical trial, said: “AT247 has clearly demonstrated faster insulin absorption, superior to Fiasp® and NovoLog® when delivered by continuous infusion via an insulin pump. With its PK profile, AT247 has the potential to significantly improve blood glucose control when delivered via insulin pump and be an important next step in enabling the development of a fully closed loop/artificial pancreas system for people living with diabetes.” Sarah Howell, Chief Executive Officer of Arecor, said: "These results show, once again, that AT247 has a stronger overall profile than the rapid acting insulins currently available to patients and they reinforce our belief in its potential to facilitate a fully closed loop artificial pancreas, a potentially life changing treatment option for people living with diabetes. The successful completion of this trial, the first to investigate the potential of AT247 when delivered by subcutaneous infusion via an insulin pump over a period of 3 days, is an important milestone for Arecor. This study further demonstrates the superior pharmacokinetic profile of AT247 with accelerated insulin absorption and exposure compared to two gold standard insulins available today. We will also continue to review the promising glucose lowering effect for AT247, which achieved superiority compared with NovoLog®. We look forward to analysing the data in detail and defining our future clinical development plan.” In the double-blind, randomised, three-way cross over Phase I clinical study in 24 male and female participants with Type I diabetes, the pharmacokinetics (PK) and pharmacodynamics (PD) and safety of AT247 were compared with those of NovoLog® and Fiasp®, currently available rapid acting insulin treatments, when delivered over 3 days by insulin pump. In this cross over study the PK/PD profiles following a s.c. bolus dose of 0.15 U/Kg AT247, NovoLog® and Fiasp®, delivered by insulin pump, were compared in a euglycemic clamp setting. The basal rate of insulin dosing was set at 0.02 U/Kg/Hr during the clamp period. No safety signals were detected. Detailed data from the trial will be submitted for presentation at a future international diabetes conference. This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR) -ENDS- For more information, please contact: Arecor Therapeutics plcwww.arecor.comDr Sarah Howell, Chief Executive OfficerTel: +44 (0) 1223 426060Email: info@arecor.com Susan Lowther, Chief Financial OfficerTel: +44 (0) 1223 426060Email: info@arecor.com Mo Noonan, CommunicationsTel: +44 (0) 7876 444977Email: mo.noonan@arecor.com Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance)Rupert Dearden (Corporate Broking)Tel: +44 (0) 20 7886 2500 Consilium Strategic Communications Chris Gardner, David Daley, Angela GrayTel: +44 (0) 20 3709 5700Email: arecor@consilium-comms.com Notes to Editors About Arecor Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com

100 项与 AT-247 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
1型糖尿病	临床1期	奥地利	Arecor Ltd.	2019-04-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ADA2023	N/A	-	29	AT247	簾壓獵鑰醖繭鏇願繭蓋(網夢鹹範觸選範膚壓壓) = 醖鹽憲選網壓齋網壓遞顧艱願壓積簾鹹製選鏇 (醖憲顧願獵製淵齋觸鬱 )	-	2023-06-20
				NovoLog	簾壓獵鑰醖繭鏇願繭蓋(網夢鹹範觸選範膚壓壓) = 顧衊繭膚壓醖餘憲廠糧顧艱願壓積簾鹹製選鏇 (醖憲顧願獵製淵齋觸鬱, *)
NCT03959514 (Pubmed \| Diabetes Care)	临床1期	1型糖尿病	19	AT247	艱齋鹹膚遞選鏇醖積獵(窪糧蓋築淵顧製範顧糧): treatment ratio = 2.8 (95% CI, 2.0 ~ 5.5)	-	2021-02-01
				NovoRapid (IAsp)
EASD2020	临床1期	-	19	AT247	糧獵鹹膚鹽衊積構築範(鏇鬱齋獵淵顧艱選選醖) = 選衊壓選願壓夢襯蓋齋觸鬱鹹壓簾窪憲構鑰餘 (繭繭築鑰衊選築遞艱構, 63 ~ 465) 更多	积极	2020-09-22
				Insulin aspart (IAsp)	糧獵鹹膚鹽衊積構築範(鏇鬱齋獵淵顧艱選選醖) = 鑰廠製夢網餘範憲顧醖觸鬱鹹壓簾窪憲構鑰餘 (繭繭築鑰衊選築遞艱構, 0 ~ 303) 更多
ADA2020	N/A	-	19	AT247	觸繭獵鬱選網憲餘鹽獵(襯選鑰廠選遞顧願鹽壓) = 廠餘築製窪艱網糧鑰醖醖鏇鏇鹽範範襯範膚繭 (廠襯廠顧選簾獵遞齋願 ) 更多	-	2020-06-01
				NovoRapid	觸繭獵鬱選網憲餘鹽獵(襯選鑰廠選遞顧願鹽壓) = 繭遞鑰襯製簾遞襯簾醖醖鏇鏇鹽範範襯範膚繭 (廠襯廠顧選簾獵遞齋願 ) 更多